{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:51:22Z","timestamp":1791899482836,"version":"4.3.4"},"reference-count":42,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Lublin","award":["DS440\/2020 and DS440\/2021-2022"],"award-info":[{"award-number":["DS440\/2020 and DS440\/2021-2022"]}]},{"name":"The Iwanowska Programme, The Polish National Agency for Academic Exchange","award":["PPN\/IWA\/2018\/1\/00005 and PPN\/IWA\/2019\/1\/00160"],"award-info":[{"award-number":["PPN\/IWA\/2018\/1\/00005 and PPN\/IWA\/2019\/1\/00160"]}]},{"name":"Polish National Science Centre (NCN)","award":["NZ4\/02364"],"award-info":[{"award-number":["NZ4\/02364"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Histone deacetylase inhibitors (HDIs) are promising anti-cancer agents that inhibit proliferation of many types of cancer cells including breast carcinoma (BC) cells. In the present study, we investigated the influence of the Notch1 activity level on the pharmacological interaction between cisplatin (CDDP) and two HDIs, valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA, vorinostat), in luminal-like BC cells. The type of drug\u2013drug interaction between CDDP and HDIs was determined by isobolographic analysis. MCF7 cells were genetically modified to express differential levels of Notch1 activity. The cytotoxic effect of SAHA or VPA was higher on cells with decreased Notch1 activity and lower for cells with increased Notch1 activity than native BC cells. The isobolographic analysis demonstrated that combinations of CDDP with SAHA or VPA at a fixed ratio of 1:1 exerted additive or additive with tendency toward synergism interactions. Therefore, treatment of CDDP with HDIs could be used to optimize a combined therapy based on CDDP against Notch1-altered luminal BC. In conclusion, the combined therapy of HDIs and CDDP may be a promising therapeutic tool in the treatment of luminal-type BC with altered Notch1 activity.<\/jats:p>","DOI":"10.3390\/ijms22105184","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:28:36Z","timestamp":1620962916000},"page":"5184","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-4577","authenticated-orcid":false,"given":"Anna","family":"Wawruszak","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3059-0393","authenticated-orcid":false,"given":"Jarogniew","family":"Luszczki","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Medical University, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Halasa","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estera","family":"Okon","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Landor","sequence":"additional","affiliation":[{"name":"Faculty of Science and Engineering, Cell Biology, \u00c5bo Akademi University, 20500 Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Sahlgren","sequence":"additional","affiliation":[{"name":"Faculty of Science and Engineering, Cell Biology, \u00c5bo Akademi University, 20500 Turku, Finland"},{"name":"Turku Bioscience Centre, \u00c5bo Akademi University and University of Turku, 20500 Turku, Finland"},{"name":"Institute for Complex Molecular Systems, Eindhoven University of Technology, 5612 Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9794-802X","authenticated-orcid":false,"given":"Adolfo","family":"Rivero-Muller","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1872-394X","authenticated-orcid":false,"given":"Andrzej","family":"Stepulak","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.arcmed.2020.08.001","article-title":"Advances in the Molecular Taxonomy of Breast Cancer","volume":"51","author":"Guido","year":"2020","journal-title":"Arch. Med Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1634\/theoncologist.2017-0535","article-title":"Luminal A Breast Cancer and Molecular Assays: A Review","volume":"23","author":"Gao","year":"2018","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"65024","DOI":"10.18632\/oncotarget.11344","article-title":"Luminal B breast cancer: Patterns of recurrence and clinical outcome","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"ref_5","unstructured":"Lim, E., and Winer, E.P. (2021, March 28). Adjuvant Chemotherapy in Luminal Breast Cancers. Available online: http:\/\/www.adjuvantonline.com."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.2147\/OTT.S145934","article-title":"Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer","volume":"ume10","author":"Huang","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.13005\/bpj\/1608","article-title":"Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin","volume":"12","author":"Aldossary","year":"2019","journal-title":"Biomed. Pharmacol. J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wawruszak, A., Kalafut, J., Okon, E., Czapinski, J., Halasa, M., Przybyszewska, A., Miziak, P., Okla, K., Rivero-Muller, A., and Stepulak, A. (2019). Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells. Cancers, 11.","DOI":"10.3390\/cancers11020148"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/13543784.2017.1386172","article-title":"Targeting triple negative breast cancer with histone deacetylase inhibitors","volume":"26","author":"Fedele","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","article-title":"Phase I Trial of Histone Deacetylase Inhibition by Valproic Acid Followed by the Topoisomerase II Inhibitor Epirubicin in Advanced Solid Tumors: A Clinical and Translational Study","volume":"25","author":"Munster","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10549-017-4516-x","article-title":"Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer","volume":"167","author":"Luu","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10549-017-4310-9","article-title":"A Phase I\/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and\/or local chest wall recurrent HER2-amplified breast cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1104)","volume":"165","author":"Goldstein","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-014-3008-5","article-title":"A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer","volume":"146","author":"Tu","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chiu, H.-W., Yeh, Y.-L., Wang, Y.-C., Huang, W.-J., Chen, Y.-A., Chiou, Y.-S., Ho, S.-Y., Lin, P., and Wang, Y.-J. (2013). Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Enhances Radiosensitivity and Suppresses Lung Metastasis in Breast Cancer In Vitro and In Vivo. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076340"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2007.10.006","article-title":"Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells","volume":"259","author":"Fortunati","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/cam4.1151","article-title":"Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1","volume":"6","author":"Jang","year":"2017","journal-title":"Cancer Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wawruszak, A., Luszczki, J.J., Kalafut, J., Okla, K., Halasa, M., Rivero-Muller, A., and Stepulak, A. (2019). Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity\u2014An Isobolographic Analysis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153663"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1242\/dev.063610","article-title":"Notch signaling: Simplicity in design, versatility in function","volume":"138","author":"Andersson","year":"2011","journal-title":"Development"},{"key":"ref_20","first-page":"195","article-title":"Effects of notch-1 down-regulation on malignant behaviors of breast cancer stem cells","volume":"34","author":"Peng","year":"2014","journal-title":"Acta Acad. Med. Wuhan"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yuan, X., Zhang, M., Wu, H., Xu, H., Han, N., Chu, Q., Yu, S., Chen, Y., and Wu, K. (2015). Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0131689"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wawruszak, A., Luszczki, J.J., Grabarska, A., Gumbarewicz, E., Dmoszynska-Graniczka, M., Polberg, K., and Stepulak, A. (2015). Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines\u2014An Isobolographic Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143013"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8345","DOI":"10.2147\/CMAR.S210029","article-title":"Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties","volume":"ume11","author":"Wawruszak","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"18814","DOI":"10.1073\/pnas.1104943108","article-title":"Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms","volume":"108","author":"Landor","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.112.193474","article-title":"Revisiting the Isobole and Related Quantitative Methods for Assessing Drug Synergism","volume":"342","author":"Tallarida","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104117","article-title":"An Overview of Drug Combination Analysis with Isobolograms","volume":"319","author":"Tallarida","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pharmthera.2006.08.002","article-title":"Interactions between drugs and occupied receptors","volume":"113","author":"Tallarida","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molonc.2010.04.004","article-title":"Histological types of breast cancer: How special are they?","volume":"4","author":"Weigelt","year":"2010","journal-title":"Mol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/BCTT.S284453","article-title":"Genetic Influences in Breast Cancer Drug Resistance","volume":"ume13","author":"Daniyal","year":"2021","journal-title":"Breast Cancer Targets Ther."},{"key":"ref_30","first-page":"2831","article-title":"Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines","volume":"6","author":"Gumbarewicz","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5306\/wjco.v5.i2.125","article-title":"Systemic treatment strategies for triple-negative breast cancer","volume":"5","author":"Yadav","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7150\/jca.16655","article-title":"Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells","volume":"8","author":"Grabarska","year":"2017","journal-title":"J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.amjsurg.2016.12.001","article-title":"Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines","volume":"213","author":"Kunnimalaiyaan","year":"2017","journal-title":"Am. J. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"996","DOI":"10.7150\/jca.12135","article-title":"The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling","volume":"6","author":"Sun","year":"2015","journal-title":"J. Cancer"},{"key":"ref_35","first-page":"1449","article-title":"[Effects of VPA on the Expression of Notch Signaling Pathway in Multiple Myeloma RPMI 8226 Cell Line]","volume":"24","author":"Qiao","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.surg.2008.08.027","article-title":"Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells","volume":"144","author":"Adler","year":"2008","journal-title":"Surgery"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1634\/theoncologist.12-8-942","article-title":"Valproic Acid Activates Notch-1 Signaling and Regulates the Neuroendocrine Phenotype in Carcinoid Cancer Cells","volume":"12","author":"Greenblatt","year":"2007","journal-title":"Oncologist"},{"key":"ref_38","first-page":"545","article-title":"HDAC inhibitors suppressed small cell lung cancer cell growth and enhanced the suppressive effects of receptor-targeting cytotoxins via upregulating somatostatin receptor II","volume":"10","author":"Sun","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bjc.6602309","article-title":"Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells","volume":"92","author":"Stockhausen","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00197-2","article-title":"Practical classification of triple-negative breast cancer: Intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies","volume":"6","author":"Marra","year":"2020","journal-title":"NPJ. Breast Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11670-012-0213-9","article-title":"Effect of trastuzumab on Notch-1 signaling pathway in breast cancer SK-BR3 cells","volume":"24","author":"Han","year":"2012","journal-title":"Chin. J. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wr\u00f3blewska-\u0141uczka, P., Grabarska, A., Florek-\u0141uszczki, M., Plewa, Z., and \u0141uszczki, J.J. (2021). Synergy, Additivity, and Antagonism between Cisplatin and Selected Coumarins in Human Melanoma Cells. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020537"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/10\/5184\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:00:37Z","timestamp":1760162437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/10\/5184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["ijms22105184"],"URL":"https:\/\/doi.org\/10.3390\/ijms22105184","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]}}}